Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — FY2025 Earnings Presentation
28 slides from Imricor Medical Systems's earnings presentation, Feb 25, 2026
Slide 1: FY 2025 Investor Presentation
FY 2025 Investor Presentation FEBRUARY 25TH 2026 For personal use only Imricor's vision is to bring iCMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer FEBRUARY 25TH 2026 The material contained in this document is a presentation of general background information on to identify forward-looking statements. These forward-looking statements reflect Imricor’s current Imricor Medical Systems, Inc. (Imricor) and its activities current as of the
Slide 3: Delivering key milestones in 2025
Delivering key milestones in 2025 FEBRUARY 25TH 2026 Regulatory & Clinical Commercial Financial • Completed integration and testing of NorthStar on For personal use only • CE Mark approval under MDR for 2nd generation • Revenue of US$292k temporarily impacted by ablation catheter and capital equipme
Slide 4: Imricor is moving cardiac ablations from X-Ray Cath Labs to MRI Cath Labs
Imricor is moving cardiac ablations FEBRUARY 25TH 2026 From X-Ray Cath Labs To MRI Cath Labs For personal use only • Boston Scientific • AtriCure 100% of consumable revenue captured • Johnson&Johnson MedTech • Kardium • Abbott • Medtronic IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 5: Imricor's solution – adding value to all stakeholders
Imricor’s solution – adding value to all stakeholders FEBRUARY 25TH 2026 For personal use only Patient Doctor Payer Hospital • Higher single procedure success rates • Improved visualisation of heart • Similar or lower per-procedure costs • Similar cost to set up an iCMR EP lab achieved in clinical t
Slide 6: Regulatory process is gaining momentum
Regulatory process is gaining momentum FEBRUARY 25TH 2026 Geography Regulation Imricor Product Suite Pathway Status Details • NorthStar For personal use only • Advantage-MR EP Recorder/Stimulator • Vision-MR Diagnostic Catheter 2.0 Med • Vision-MR Diagnostic Cable Full technology platform to perform
Slide 7: Board of directors strengthened to support growth and commercialisation
Board of directors strengthened to support FEBRUARY 25TH 2026 growth and commercialisation For personal use only “Throughout my 30-year career at companies such as Medtronic and Johnson & Johnson MedTech, I have witnessed remarkable innovations that have reshaped the landscape of healthcare and impr
Slide 8: Financial Performance
Financial FEBRUARY 25TH 2026 Performance For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 9: Profit and loss
Profit and loss FEBRUARY 25TH 2026 US$’000 FY25 FY24 Commentary Revenue 292 959 • Revenue decrease on prior comparative period (pcp) is the result of customer sites enrolling trial patients, a 3rd party For personal use only Costs and non-R&D expenses (11,418) (8,643) capital sale in Europe and a co
Slide 10: Balance sheet
Balance sheet FEBRUARY 25TH 2026 US$’000 Dec-25 Dec-24 Cash and cash equivalents 19,502 15,708 Commentary Marketable securities 21,278 - • Cash, cash equivalents, and marketable securities balances Accounts receivable 241 345 total $40.8 million For personal use only Inventory 1,096 1,502 • Converti
Slide 11: Cash flow
Cash flow FEBRUARY 25TH 2026 US$’000 FY25 FY24 Commentary Net loss (25,319) (29,693) • Other non-cash adjustments were down vs. pcp primarily Other non-cash adjustments 6,339 14,889 due to decreases in the change in fair value charges. For personal use only • Purchases of marketable securities were
Slide 12: Looking ahead to 2026 & beyond
Looking ahead to FEBRUARY 25TH 2026 2026 & beyond For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 13: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation FEBRUARY 25TH 2026 A large global addressable market with high growth potential supported by favourable growth drivers For personal use only Drivers of global catheter ablation market Electrophysiology Devices Market Size US$bn 40 35 15% CAGR Increased
Slide 14: Pipeline benefiting from investment in sales
Pipeline benefiting from investment in sales FEBRUARY 25TH 2026 European active pipeline is rebuilding For personal use only Imricor’s products are currently approved in 31 countries, with 8 45 countries containing customer sites 40 Estimated over 1,500,000 ablation 35 procedures across the US, EU a
Slide 15: VISABL-AFL Clinical Trial Sites – Atrial Flutter sets the stage
VISABL-AFL Clinical Trial Sites – Atrial Flutter sets the stage FEBRUARY 25TH 2026 DR. AV KOLANDAIVELU DR. AJAY PILLAI DR. MARCO GÖTTE PROF. JUERG SCHWITTER Johns Hopkins University Virginia Commonwealth University Health Amsterdam University Medical Center MD, Director Cardiac MR Centre, For person
Slide 16: Ventricular Tachycardia changes the game
Ventricular Tachycardia changes the game FEBRUARY 25TH 2026 VT & AF Limited soft tissue view ≈ $2,000 / case For personal use only Left-sided access is required X-ray fluoroscopy can’t show the septum nor ICE adds guidance …. and cost the heart Most VT and AF ablations target the left side of With X
Slide 17: Ventricular Tachycardia changes the game
Ventricular Tachycardia changes the game FEBRUARY 25TH 2026 Scar channels 3D mapping Catheters + time For personal use only ≈ $2000 VT substrate is hard to find Hundreds of points per case Mapping adds cost and hours Scarring on the heart can form narrow channels With fluoroscopy blind to myocardium
Slide 18: The Imricor solution
The Imricor solution FEBRUARY 25TH 2026 Full MRI of heart Shell creation & scar identification Targets ablated under real-time For personal use only in NorthStar MRI imaging MRI used to cross the septum Shells created from the actual heart images Ablation under real-time MRI guidance No need for ICE
Slide 19: iCMR Lab Economics
iCMR Lab Economics FEBRUARY 25TH 2026 better outcomes, higher throughput, higher margins For personal use only US Top 50 Hospitals by volume AFL VT Afib Total Average procedures pa 434 173 1010 1617 Imricor estimated ASP US$ per procedure $4000 $6500 $6500 Revenue opportunity per hospital for Imrico
Slide 20: NorthStar – Cleared and ready for commercialisation
NorthStar – Cleared and ready for commercialisation FEBRUARY 25TH 2026 NorthStar Key piece of the infrastructure, intended to be the For personal use only central hub of every iCMR lab Mapping System AI powered application potential well beyond cardiac ablation Strong in-bound interest from hospital
Slide 21: Several key value drivers during 2025/26
Several key value drivers during 2025/26 FEBRUARY 25TH 2026 FDA Approval for US commercial release of New site activations, growing installed base For personal use only platform technology globally • 510(k) submissions / approvals • VISABL-AFL clinical trial expands in U.S. • PMA submissions / appro
Slide 22: Questions?
Questions? FEBRUARY 25TH 2026 For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 23: Appendix
Appendix FEBRUARY 25TH 2026 For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 24: A strong intellectual property portfolio
A strong intellectual property portfolio FEBRUARY 25TH 2026 Imricor’s patents protect technology that allows Imricor to For personal use only manufacture medical devices that are uniquely MRI compatible. Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat be
Slide 25: Imricor Leadership: Management
Imricor Leadership: Management FEBRUARY 25TH 2026 STEVE WEDAN GREG ENGLEHARDT NICK TWOHY JENNIFER WEISZ VIC FABANO For personal use only President and Chief Executive Vice President of Global Sales Vice President of Marketing Vice President of Regulatory and Vice President of Operations Officer, and
Slide 26: Imricor Leadership: Board of directors
Imricor Leadership: Board of directors FEBRUARY 25TH 2026 For personal use only STEVE WEDAN MARK TIBBLES PETER MCGREGOR ANITA MESSAL JEFFREY LEIGHTON ALDO DENTI President and Chief Executive Deputy Chair and Lead Non-executive Director Non-executive Director Non-executive Director Non-executive Dire
Slide 27: Key terms
Key terms FEBRUARY 25TH 2026 • Medical device developed by Imricor, designed for use within an MRI Vision-MR Ablation Catheter • World first, no competitors, all others only compatible with X-ray • Irregular heartbeat, affects approximately 2% of US population For personal use only • Expected to dou
Slide 28: Contact information
Contact information FEBRUARY 25TH 2026 Investors & Australian Media: For personal use only Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Nick Corkill Vice President, Corporate Str
Imricor Medical Systems — FY2025 Earnings Presentation on 6ix